Connect with us

Technology

Implantica announces excellent RefluxStop™ investigator initiated study results published in Scientific Reports, a Nature journal

Published

on

VADUZ, Liechtenstein, July 30, 2024 /PRNewswire/ — Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, announces the independent study ‘Multicentric short term and safety study of ineffective esophageal motility (IEM) patients treated with RefluxStop device’ was recently published in Nature Scientific Reports.

This investigator-initiated independent multicenter study was conducted at the General Hospital of the Medical University of Vienna, Austria, and King Edward VII Hospital in London, UK, from 2021 through 2023. All 40 patients had Ineffective Esophageal Motility (IEM) preoperatively, a notoriously difficult-to-treat subgroup of GERD patients.

Three months after the RefluxStop™ procedure, symptoms completely resolved or improved in 90% of the patients, PPI consumption was reduced by 84% and Quality of Life GERD-HRQL score was reduced from 32.8 to 6.6, an improvement of 80%, with limited side effects.

Patients with ineffective esophageal motility (IEM) have a weaker transportation of food down the esophagus and, therefore, often have swallowing difficulties. These patients are usually not recommended for surgery with standard of care surgical methods because they encircle and put pressure on the food passageway causing swallowing problems to worsen. This patient group comprises about one-third of the acid reflux sufferers that have no well working treatment today.

Prof. Dr. Sebastian Schoppmann of the Medical University of Vienna says, “It’s exciting to conduct the first real-world multicenter study assessing the safety and efficacy of the RefluxStop procedure. We found patients treated with RefluxStop experienced substantial improvements in quality of life and reflux symptoms with minimal safety issues despite all having ineffective esophageal motility. IEM is a well-known group of patients without any effective treatment options.” He adds, “Given RefluxStop’s great promising early results showing significant improvement in patient outcomes in GERD, we are now planning additional studies to validate our findings further and hopefully establish this as an effective treatment option to help the widely underserved GERD patient population.”

Dr. Peter Forsell, inventor of RefluxStop™ and CEO & Founder of Implantica adds, “It is exciting to see how well RefluxStop treats IEM patients with limited side effects since it does not encircle the food passageway like existing standard of care surgical treatments. Since launch several hundred patients with IEM have been operated with RefluxStop and the results have been excellent. We are very pleased to see these results published in Scientific Reports, a journal of Nature portfolio, which is a hallmark of high-quality research work, and would like to thank Prof Schoppmann and Dr. Boyle for their dedicated work. It is satisfying to see the RefluxStop procedure used for GERD patients with esophageal motility disorders given that historically these patients were largely excluded from the existing anti-reflux surgical treatments. RefluxStop™ has established itself as a great hope for these difficult-to-treat patients as well as millions of other GERD patients who would benefit from the RefluxStop procedure with its unique mechanism of action.”

For further information, please contact:
Nicole Pehrsson, Chief Corporate Affairs Officer
Telephone (CH): +41 (0)79 335 09 49
nicole.pehrsson@implantica.com

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The company’s Certified Adviser is FNCA Sweden AB, info@fnca.se

The information was sent for publication, through the agency of the contact person set out above, on July 30, 2024, at 08:00 a.m. (CET).

About Implantica

Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica’s lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energizing platform designed to power remote-controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.

About RefluxStop™

RefluxStop™ is a new innovative treatment that has the potential to spur a paradigm shift in anti-reflux surgery. It’s unique mechanism of action differentiates it from standard of care and current surgical solutions. Longer established surgical options for GORD involve encircling the food passageway to support the lower oesophageal sphincter’s closing mechanism and are commonly associated with side effects such as swallowing difficulties, pain when swallowing and inability to belch and/or vomit.

In contrast, the RefluxStop™ device treats the cause of acid reflux without encircling and putting pressure on the food passageway. It restores and maintains the lower oesophageal sphincter in its original, natural position.

The RefluxStop™ mechanism of action is focused on reconstructing all three components of the anti-reflux barrier, that if compromised could possibly result in acid reflux. It restores and supports the natural anatomical physiology of the body allowing the body to itself solve the problem with acid reflux.

Newsroom
https://www.implantica.com/media/media-kit

Community
https://ch.linkedin.com/company/implantica
https://www.twitter.com/implantica

Media Contact:
Implantica AG
Juanita Eberhart, VP Marketing & Advocacy
M: +1 925-381-4581
juanita.eberhart@implantica.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/implantica/r/implantica-announces-excellent-refluxstop–investigator-initiated-study-results-published-in-scienti,c4019504

The following files are available for download:

https://mb.cision.com/Main/19732/4019504/2928914.pdf

Implantica announces excellent RefluxStopâ„¢ investigator initiated study results published in Scientific Reports, a Nature journal

https://news.cision.com/implantica/i/logo-transparent-1-8,c3321935

logo transparent 1 8

https://news.cision.com/implantica/i/reluxstop-product,c3321938

ReluxStop Product

 

View original content:https://www.prnewswire.co.uk/news-releases/implantica-announces-excellent-refluxstop-investigator-initiated-study-results-published-in-scientific-reports-a-nature-journal-302209601.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Higer New V Series, Leading Bus New Trend

Published

on

By

SUZHOU, China, Dec. 24, 2024 /CNW/ — In November 2024, Higer New V Series buses officially launched in the Philippines, this batch of electric buses was the first batch of new energy buses introduced by the Philippines and put into commercial operation. And it has aroused extensive attentions and heated discussions from the Philippines local government, media and people.

Higer New V Series products were launched globally in March 2024, and then made a stunning debut at the Higer Global Partners Conference. The New V-series products with a new shape and a new platform are committed to creating new classic models with high quality, high safety and high intelligence.

In 3 years, more than 1000 people participated in the process of R&D, a one-time investment of more than 100 million yuan was made in the R&D and manufacturing of key components, equipment, tooling, molds, inspection tools, verification of components and vehicle, achieving comprehensive innovation, realizing a significant improvement in product quality and reliability, maintenance convenience and customer experience. Measuring from 8 to 13 meters in length, they can be powered by fossil fuels, electricity, hydrogen, etc. and are readily adaptable for the tourist transportation market, urban public transportation market, etc. The luggage compartment volume is 21.6% greater than similar products, the seating space is 50mm larger, and the middle aisle is 30mm wider. The overall component universality rate was greatly improved by the platform, modular, and universal design concept, and the number of component types decreased by 58%.

It is worth mentioning that Higer is committed to creating a technological experience, redefining the domain-centralized electronic and electrical architecture, and Higer launched the industry’s first mass-produced intelligent cabin. It will help the driver concentrate on driving. The new model provides a mobile phone control interface, drivers and tour guides can control lighting, multimedia, air conditioning, etc. through app. In addition, the intelligent cabin can be customized according to the operational needs of the transport company, realizing intelligent dispatching, intelligent charging, intelligent maintenance, AI interaction, and human-computer interaction.

So far, Higer new V series coaches have already received orders from more than 20 countries like Italy, Qatar, UAE, Saudi Arabia, Algeria and etc., showing a fast rising popularity in the international market.

Higer new V series are committed to providing customers with new “classic models” with better quality, higher efficiency, achieving sustainable development and exploring more possibilities.

View original content to download multimedia:https://www.prnewswire.com/news-releases/higer-new-v-series-leading-bus-new-trend-302339047.html

SOURCE HIGER

Continue Reading

Technology

European Wellness Biomedical Group Announces New Klotho Research Initiative Led by Prof. Mike Chan

Published

on

By

HEIDELBERG, Germany, Dec. 25, 2024 /PRNewswire/ — European Wellness Biomedical Group (EWBG) has launched a new research initiative focused on Klotho, a protein with transformative potential in longevity medicine. Led by Professor Dr. Mike Chan, this project will explore Klotho’s role in combating age-related diseases and its ability to regenerate critical organs, including the brain, kidneys, and heart.

Klotho, identified in 1997, is emerging as a key protein in longevity and regenerative medicine. It plays a pivotal role in regulating oxidative stress, mineral metabolism, and inflammation. The research will investigate how boosting Klotho levels could help address chronic conditions like neurodegenerative diseases, kidney failure, and heart disease, ultimately improving healthspan and extending lifespan.

“Klotho represents the next frontier in longevity medicine,” said Professor Mike Chan, Chief Scientist at EWBG. “Our research aims to understand how Klotho affects aging and how we can use it to treat chronic diseases that have long been associated with aging.”

Research Focus Areas

The new initiative will focus on three primary research areas:

Neurological health: Investigating Klotho’s neuroprotective effects and its potential to slow cognitive decline in diseases like Alzheimer’s and Parkinson’s.Kidney function: Examining Klotho’s role in regulating mineral metabolism and its regenerative potential in treating chronic kidney disease (CKD).Cardiovascular health: Studying Klotho’s influence on vascular function and its ability to prevent vascular calcification, a key contributor to heart disease.

This research builds on existing collaborations at EWBG, where leading scientists focus on advancing Klotho-based therapies for regenerative health.

Klotho: A Potential Breakthrough in Longevity Medicine

Klotho is gaining attention for its ability to regenerate tissues and reverse damage caused by age-related diseases. Unlike NAD+, which primarily enhances cellular metabolism and energy production, Klotho offers a broader range of therapeutic applications, including tissue regeneration, cognitive function improvement, and cardiovascular health.

As we age, Klotho levels naturally decline, leading to conditions such as cognitive decline, heart disease, and kidney failure. Research suggests that restoring Klotho levels can reverse the effects of oxidative stress, inflammation, and cellular senescence, offering new treatment possibilities for a range of age-related diseases.

Professor Mike Chan: Leading the Charge in Klotho Research

Professor Mike Chan, a leading expert in stem cell therapy and longevity medicine, is spearheading this groundbreaking initiative at EWBG. His extensive experience in bio-regenerative medicine positions him as a key figure in exploring Klotho’s potential to revolutionize the treatment of age-related diseases. Through FCTI, a subsidiary of EWBG, Professor Chan and his team are developing therapies that combine stem cell technology and Klotho proteins to stimulate tissue regeneration in the brain, kidneys, and heart.

“By harnessing Klotho’s regenerative properties, we hope to address chronic conditions that were previously untreatable,” said Professor Chan. “Our ultimate goal is to improve quality of life and provide lasting solutions for those affected by aging-related diseases.”

The Future of Klotho in Longevity Medicine

The future of Klotho-based therapies looks promising, with Professor Mike Chan and EWBG at the forefront of this innovative field. As more research is conducted, Klotho is expected to play a pivotal role in advancing longevity medicine, offering a new approach to treating aging and chronic diseases. The potential applications of Klotho are vast, from neurodegenerative disease treatment to kidney regeneration and cardiovascular health.

With strong research partnerships, significant funding, and ongoing clinical trials, Klotho is poised to become a cornerstone of longevity medicine, transforming how we approach aging and disease. Professor Mike Chan’s leadership ensures that this promising protein will soon offer new hope to those seeking longer, healthier lives.

Photo – https://mma.prnewswire.com/media/2587407/Prof_Dr_Mike_Chan_talks_growing_importance_Klotho_anti_aging_medicine.jpg

Logo – https://mma.prnewswire.com/media/2362609/EW_COLOR_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/european-wellness-biomedical-group-announces-new-klotho-research-initiative-led-by-prof-mike-chan-302338980.html

Continue Reading

Technology

Apas Port Launches $20M Vehicle Loan Initiative with HARVEST FLOW on Plume Network to Empower Financial Inclusion in Emerging Countries, Starting in Cambodia

Published

on

By

NEW YORK, Dec. 24, 2024 /PRNewswire/ — Apas Port Co., Ltd., a Tokyo-based Web3 company dedicated to deploying “kando”—a Japanese term for deep emotional engagement—into the digital realm, has announced the launch of HARVEST FLOW, a social impact-driven cryptocurrency lending platform. Committed to “social action”ーdelivering stable returns alongside meaningful social impact, HARVEST FLOW’s inaugural project is a $20 million initiative offering loans to TukTuk and four-wheel vehicle drivers in Cambodia who don’t have access to the financial system. This venture is set to operate on Plume Network, the leading Layer 1 blockchain specialized in Real-World Asset Finance (RWAfi), offering the necessary infrastructure to transform HARVEST FLOW’s vision of financial inclusion into scalable action.

Bridging Real-World Challenges Through Blockchain Innovation

HARVEST FLOW’s mission is to empower underserved communities and small businesses by granting access to affordable financing solutions. By leveraging blockchain technology, the platform addresses critical societal issues such as poverty alleviation and economic development, creating pathways for stable financial growth while delivering measurable social impact.

The initial focus of this initiative is to provide affordable financing options for TukTuk and four-wheel vehicle drivers in Cambodia—vital tools for local livelihoods. The project not only supports job creation but also enhances financial inclusion in emerging economies.

Why Plume Network?

As the first fully integrated L1 modular blockchain tailored for RWAfi, Plume Network provides the foundation for scalable, secure, and transparent financial ecosystems. With over 180 projects onboarded in its private devnet, Plume enables seamless tokenization and distribution of RWAs through its composable, EVM-compatible infrastructure.

How Plume Powers HARVEST FLOW:

End-to-End Tokenization: Streamlines the conversion of vehicle loans into blockchain-based assets.Investor Transparency: Advanced tools to track and visualize the social and financial impact of investments.Global Scalability: Infrastructure designed to handle the growing demands of HARVEST FLOW’s multi-region projects.DeFi Integration: Unlocks liquidity through decentralized finance primitives within the Plume ecosystem.

IoT-Backed Innovation for Loan Security

HARVEST FLOW’s projects are uniquely supported by embedded IoT technology within TukTuk engines, ensuring an exceptionally low loan default rate while building investor confidence.

Justin Chen, Head of Asset Strategy at Plume Network, noted: “This project highlights the power of combining blockchain and IoT devices to create innovative financial products that drive real-world impact. We’re excited to see HARVEST FLOW’s success on Plume and the positive change it will bring to the urban motility market in Southeast Asia.”

Looking Ahead

Starting with the vehicle mobility sector through 2025, HARVEST FLOW plans to expand into other sectors addressing social challenges and needs beyond 2026. This approach aims to ensure sustainable growth while delivering meaningful societal benefits, powered by Plume’s blockchain technology.

Masaki Minamide, director of HARVEST FLOW, stated: “Plume’s infrastructure empowers us to amplify our impact and support communities in need while offering our investors transparent and reliable returns. With this launch, we continue our mission to combine blockchain technology with meaningful social action.”

For more information, visit Plume Network or contact press@plumenetwork.xyz.

About Plume Network
Plume is the first fully integrated L1 modular blockchain focused on RWAfi, offering a composable, EVM-compatible environment for onboarding and managing diverse RWAs. With 180+ projects on its private devnet, Plume provides an end-to-end tokenization engine and a network of financial infrastructure partners, simplifying asset onboarding and enabling seamless DeFi integration for RWAs.

About HARVEST FLOW
Founded in April 2023, Apas Port Co., Ltd. is a Web3 production company with a mission to deploy “kando” (deep emotional impact) globally. The company leverages blockchain technology to connect carefully curated content with a co-creative community, acting as a “passport” to a new world of Web3 experiences.

X: https://x.com/HarvestFlow_io
Website: https://www.harvestflow.io/

View original content to download multimedia:https://www.prnewswire.com/news-releases/apas-port-launches-20m-vehicle-loan-initiative-with-harvest-flow-on-plume-network-to-empower-financial-inclusion-in-emerging-countries-starting-in-cambodia-302339001.html

SOURCE Plume Network

Continue Reading

Trending